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Abstract 
Acute brain injury is a major cause of death and disability with one of the most 
damaging aspects being elevated intracranial pressure (ICP). In patients with refractory 
elevated ICP, methods such as induced therapeutic hypothermia (TH) are often utilized 
for several days. It has also been shown that hyperglycemia and glucose variability are 
associated with poor neurologic outcomes in patients with acute brain injury. This is of 
further concern in patients undergoing TH as TH has been shown to cause a decrease in 
insulin production and increased insulin resistance. However, current literature only 
exists in post-cardiac arrest patients who underwent hypothermia for 24 hours. The 
effects of TH over several days on glycemic control are unknown. This study will 
examine the effects of prolonged TH in patients with acute brain injury on glycemic 
control.  
This is a retrospective cohort study of adult patients with acute brain injury 
admitted to UNC Hospitals from May 2010 to August 2013 who underwent TH for >24 
hours. Exclusion criteria included history of type 1 diabetes, presentation with DKA or 
HHS, or administration of steroids for >24 hours or TPN. Data was collected at baseline 
and across four phases for TH patients (pre-TH, induction, maintenance, rewarming and 
post-TH) and across three phases for CN patients (pre-CN, CN phase, and post-CN). 
Sixteen patients met inclusion criteria. The mean age was 41±18 years and TBI 
accounted for 56.3% of the admitting diagnoses. The mean days from injury to cooling 
was 2.8±2.4 days. Median BG (143±25.5 vs. 110±35.25 vs. 116.5±28.8 mg/dL) and BG 
variability (82±71 vs. 46±53 vs. 61±29 mg/dL) were higher during pre-TH compared to 
TH and post-TH, respectively. Nine patients during pre-TH and TH and 7 patients during 
post-TH required insulin.  
 
Introduction 
Acute brain injuries are a leading cause of mortality in the US, with strokes 
accounting for 128,000 deaths1 and traumatic brain injuries accounting for 53,000 
deaths.2 In acute brain injuries, there is neurologic sequelae after the initial insult. 
Cerebral edema and elevated intracranial pressure (ICP) is a common secondary 
complication of acute brain injuries. Normal ICPs are usually less than 15 mmHg, while 
an elevated ICP greater than 20 mmHg can have life-threatening consequences. 
Uncontrolled swelling can result in herniation and irreversible damage to the brain stem.  
Sustained elevated ICPs can also cause a decrease in cerebral blood flow and cerebral 
perfusion pressure, resulting in cerebral ischemia. There are various approaches to 
managing elevated ICP. First line strategies usually include increased sedation and 
hyperosmotic therapy with mannitol or hypertonic saline. Other strategies for the 
management of elevated ICP include ventricular drainage and barbiturates. Induced 
hypothermia may be used in refractory elevated ICP situations.3   
Therapeutic hypothermia (TH) is the intentional cooling of a patient to a 
controlled temperature of 32-35°C. It decreases cerebral edema and ICP by causing the 
overall reduction in excitotoxic neurotransmitter release, free radical formation, sustained 
electrical depolarizations, and inhibition of proinflammatory and apoptotic pathways. 
There are various systems to induce hypothermia, but most systems cool the body by 
conductive heat loss via either surface pads or intravascular heat exchange catheters. 
Additionally, intravenous infusions of cold fluids can be given to decrease the time it 
takes to reach the target temperature. The time course of TH can be divided into three 
phases (Figure 1). The first phase is induction, where the body’s core temperature is 
quickly lowered to the target temperature over the course of an hour or two. This is 
followed by the second phase, maintenance, where the body is maintained at the target 
temperature. After the maintenance phase, there is a prolonged rewarming phase as the 
body’s core temperature is slowly allowed to return to normal. The rate of rewarming 
during this last phase must be slow (0.1-0.25°C/hour) to prevent electrolyte 
abnormalities, rebound ICP, and other adverse effects. TH is not without its adverse 
effects. There are decreases in electrolytes levels, and platelet counts, changes in drug 
metabolism, and increases in the risk of infection, blood pressure, PR and QT intervals, 
and blood glucose.4  
Blood glucose can be difficult to control in all critically ill patients. 
Hyperglycemia is common in these patients as part of the physiological stress response. 
The release of steroids, catecholamines, and cytokines increases the production of 
glucose. Additionally, because critically ill patients are largely immobile, there is 
decreased utilization of blood glucose by skeletal muscle, the largest consumer of 
glucose.5 In the face of these physiological effects, blood glucose control has been shown 
to be important in acute brain injury patients. Both hyperglycemic (>200mg/dL) and 
hypoglycemic (<80mg/dL) events are associated with poor outcomes.6 High variability, 
or large swings, in blood glucose is another independent risk factor associated with poor 
outcomes in acute brain injury patients.7 TH further complicates blood glucose 
management in acute brain injury patients by decreasing insulin production and 
increasing insulin resistance, compounding the hyperglycemia.4 
The glycemic effects of TH have been characterized in post cardiac arrest 
patients.8,9 Short-term hypothermia in post cardiac arrest patients is associated with 
higher blood glucose levels, increased blood glucose variability, and greater insulin 
requirements compared to normothermia. However, in this application, the maintenance 
phase of hypothermia only lasts 12-24. In contrast to cardiac arrest, the maintenance 
phase of TH in patients with acute brain injuries can last days to weeks. It is unknown 
how undergoing TH for a prolonged period effects blood glucose. The objective of this 
study is to evaluate the effects of prolonged hypothermia on glycemic control and insulin 
requirements in patients with acute brain injury. 
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Methods  
Patient Population 
Patients for this single-center, retrospective chart review were included if they 
were admitted to the neurosciences intensive care unit at UNC Hospitals in Chapel Hill, 
NC between May 1, 2010 and August 31, 2013, at least 16 years old, and underwent TH 
for at least 48 hours. Patients were excluded if they had a history of type 1 diabetes, 
presented with DKA or HHS upon admission, received an insulin pump, received total 
parenteral nutrition during the study observation period, received systemic steroids for 
greater than 24 hours during the study observation period, or were on home systemic 
steroids 
 
Protocols 
Therapeutic hypothermia was controlled using the Arctic Sun system (Medivance, 
Louisville, CO). Target temperatures and duration were chosen at the discretion of the 
medical team.  
Short-acting subcutaneous insulin and intravenous insulin infusion rates were dosed 
per institutional protocols (Supplemental appendix 1 and 2). Long-acting subcutaneous 
insulin was dosed at the discretion of the medical team. 
 
Data collection 
Baseline characteristics collected included age, gender, weight, type of acute 
brain injury, severity of injury based on the Glasgow Coma Scale (GCS) and Sequential 
Organ Failure Assessment (SOFA), and initial lab values (including Hgb A1c, serum 
blood glucose, and electrolytes). 
The study observation period was defined as three different time periods: up to 48 
hours before the initiation of induction (pre-cooling), maintenance phase and up to 48 
hours after rewarming (post-warming). The rewarming phase was not included as it is a 
short window with few data points. During the study observation period, all blood 
glucose levels (from fingerstick readings, levels from regular metabolic panels, and levels 
from arterial blood gases), the type, route, and dose of insulin administered, ICPs, body 
temperature, brain oxygenation (PbtO2), GCS,  
Clinical outcomes examined included length of ICU and hospital stay, discharge 
disposition, and modified Rankin Scale (mRS) at discharge. 
 
Statistical analysis 
Median daily blood glucose levels and median daily blood glucose variability were 
determined for each of the three time periods. Daily variability was defined as the 
difference between the maximum and minimum blood glucose readings in each 24-hour 
period.  
 
Results 
Sixteen patients were included in this study. Patient characteristics are shown in 
Table 1. The median blood glucose for the pre-cooling, maintenance, and post-warming 
were 143±25.5 mg/dL, 110±35.25 mg/dL, and 116.5±28.8 mg/dL respectively. Median 
daily variability of blood glucose for the pre-cooling, maintenance, and post-warming 
were 82±71 mg/dL, 46±53 mg/dL, and 61±29 mg/dL respectively. (Table 2) 
During the pre-cooling phase, 9 patients required any insulin therapy, 5 of which 
required intravenous insulin, and median daily dose was 18 units/day (IQR: 4–29.6 
units/day). During the maintenance phase, 9 patients required any insulin therapy, 6 of 
which required intravenous insulin, and the median daily dose was 34 units/day (IQR: 4–
62 units/day). During the post-cooling phase, 7 patients required any insulin therapy, 2 of 
which required intravenous insulin, and the median daily dose was 4 units/day (IQR: 2–6 
units/day). In patients requiring insulin therapy, the median blood glucose for the pre-
cooling, maintenance, and post-warming were 147±34 mg/dL, 133±35.5 mg/dL, and 
132±10.5 mg/dL respectively, and the median daily variability of blood glucose for the 
pre-cooling, maintenance, and post-warming were 96±111 mg/dL, 75±68 mg/dL, and 
61±22 mg/dL respectively. 
 
Phase Median blood glucose (mg/dL) 
Median daily variability of 
blood glucose (mg/dL) 
Pre-cooling 143±25.5 82±71 
Maintenance 110±35.25 46±53 
Post-warming 116.5±28.8 61±29 
   Table 2 – Overall median blood glucose and variability for each phase 
 
During the pre-cooling phase, 1 patient had a hypoglycemic event and 7 patients 
had a hyperglycemic event. During the maintenance phase, 3 patients had a 
hypoglycemic event, all of which were being given intravenous insulin and 5 patients had 
a hyperglycemid event. During the post-warming phase, zero patients had a 
hypoglycemic event and 3 patients had a hyperglycemic event. 
 The mean length of hospital stay was 24.3±26.5 days, and the mean ICU stay was 
14.7±8.5 days. 11 patients died during the course of the hospital stay, and 12 patients had 
a mRS of 5 or greater (severe disability or death) at discharge. 
Variable (n = 16) 
Age, yrs, mean (SD) 40.9 (17.85) 
Male gender, n (%) 11 (68.8) 
Type II Diabetes Mellitus, n (%) 2 (12.5) 
Admitting GCS, median (range) 4.5 (3-10) 
Admitting SOFA Score, median (range) 7.0 (3-11) 
Admission glucose, median (IQR) 136 (65) 
Admitting diagnosis: n (%)  
      TBI, n (%) 9 (56.3) 
      aSAH, n (%) 2 (12.5) 
      ICH, n (%) 3 (18.8) 
      AIS, n (%) 2 (12.5) 
Days from Injury to Cooling, mean (SD) 2.8 (2.4) 
Duration of Cooling, days, median (range) 4.0 (1.5-12.5) 
Temperature in Maintenance Phase, mean (SD) 33.9 (0.9) 
  Table 1 – Patient characteriestics 
 
Conclusions 
In this study, the highest median BG and variability were in the pre-cooing phase 
compared to the maintenance and post-cooling phases. This reflects the significant effects 
of stress hyperglycemia during the acute phase of injury and that the physiologic 
response to stress has the greatest impact on blood glucose levels and variability. There 
was also an increase in insulin utilization during the maintenance phase. This is in line 
with what was expected due to the insulin effects on glycemic control in patients treated 
with TH. While there was a decrease in the number of patients requiring insulin in the 
post-cooling phase, it may be impacted by the mortality rate of the patients during the 
maintenance phase rather than patients regaining the ability to autoregulate blood glucose 
levels after the end of TH. 
Patients requiring insulin had increased daily variability in blood glucose 
compared to patients who did not require insulin. Patients that have hyperglycemia 
requiring insulin may have impaired self-regulation in glucose production and utilization, 
making them intrinsically more difficult to manage, but it also raises the important 
possibility that the insulin intervention in this study was iatrogenically creating larger 
variability in these patients. Further underscoring the risks of insulin therapy in this 
study, all three patients that experienced hypoglycemic events during the maintenance 
phase were patients being given intravenous insulin. 
In the future, larger studies should be performed to better correlate these 
observations with clinical outcomes, as they have been able to do in post cardiac arrest 
resuscitation. More information on glycemic control in these patients may also help us 
better optimize protocols for glycemic control for patients with acute brain injuries 
treated with TH. 
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Appendix 1: Standard Sliding Scale Insulin protocol 
 
If blood glucose is (mg/dL) Give 
0-50 Dextrose 50% 
51-80 Juice or crackers 
81-150 0 units insulin 
151-200 2 units insulin 
201-250 4 units insulin 
251-300 6 units insulin 
301-350 8 units insulin 
351-400 10 units insulin 
≥401 12 units insulin 
  
Appendix 2: 
 
C 
   
 
TARGET                   GLUCOSE 140 – 180 mg/dL  
Titration Schedule 
x Start insulin infusion at Column 2 (Default) or physician-ordered initial column 
x CAPILLARY BLOOD GLUCOSE Q1hr UNTIL 1st CBG reaches 140-180 mg/dL range or after any column reassignment.  Use consistent blood source for testing: arterial , venous or capillary .(If venous source used ensure not drawn from line where  dextrose infusing)       
x IF CBG >=230 mg/dL X 1 Hr AND NOT FALLING at least 30mg/dL over 1 hr, go to next higher column. 
x IF CBG > =180 mg/dL X 2 Hr AND NOT FALLING at least 60mg/dL over 2 hr, go to next higher column 
x Notify MD if pt on column 6 and CBG >220 mg/dL X2 Hr AND NOT FALLING at least 60 mg/dl 
x Notify MD if CBG < 70 mg/dL and treat with D50W per medication orders.  Obtain CBG q5 min until CBG > 70 mg/dL 
x If infusion turned off per protocol and not d/c, check CBG q1h until CBG >150mg/dL, then resume at next lower column.  If already on column 1, restart at rate associated with most recent CBG and notify MD.   
x If on Column 4, 5, or 6 and no column change X 8 Hr AND CBG < 150 mg/dL, go to next lower column 
x Change CBG to q2h when target range reached and no column change X 4 hours 
x Decrease insulin infusion to the next lower column assignment & resume titration schedule if the following occur: 
o Interruption of tube feeds   
 Notify MD to consider starting a dextrose-containing fluid until tube feeds are resumed 
o IV dextrose rate reduction t 50%  
o Glucocorticoid dosage reduction by t 50%  
o Increase in insulin dosage in TPN by >35 units 
x Notify MD prior to discontinuing insulin infusion for SQ insulin orders 
o If regular insulin, then discontinuation of insulin infusion therapy 1 hour after administration 
o If isophane (NPH), or glargine insulin then discontinuation of insulin infusion therapy 2 hours after administration   
Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 CBG Units/h CBG             Units/h CBG Units/h CBG Units/h CBG Units/h CBG Units/h < 120 Off < 120 Off < 120 Off < 120 Off < 120 Off < 120 Off 120-149 Off 120-149 Off 120-149 1 120-149 2 120-149 3 120-149 4 150-179 0.5 150-179 1 150-179 2 150-169 3 150-169 4 150-169 6     170-189 4  170-189             5 170-189 8 180-209 1 180-209 2 180-209 3 190-209 5 190-209 6 190-209 10 210-269 2 210-254 2.5 210-239 4 210-239 6 210-239 8 210-229 12   240-269 5 240-269 8 240-269 10 230-249 14 270-329 3 255-299 3 270-299 6 270-309 10 270-299 12 250-269 16  300-345 4 300-329 7 310-329 12 300-329 14 270-309 18 330-389 4  330-359 8 330-349             13 330-359 16 310-349 22  346-389 5 360-389 9 350-389 14 360-389 18 350-389 26 >= 390 5 >= 390 6 >= 390 10 >= 390 16 >= 390 20 >= 390 32  
ALGORITHIM FOR ORDER TO TREAT PATIENT IF CBG < 70 mg/dL 
 Administer 12.5 g (25 mL) of 50% dextrose IV PRN 
 Re-check CBG q 5 minutes until > 70 mg/dL 
 Repeat Dose until CBG > 70 mg/dL  
Intravenous Insulin Infusion Titration for 
Critically Ill Adults 
Revised May 14, 2013  
